Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Bardet-Biedl syndrome (BBS; MIM 209900) is a rare ciliopathy characterized by retinitis pigmentosa, postaxial polydactyly, obesity, hypogonadism, cognitive impairment and kidney dysfunction. Mutations in 22 BBS genes have been identified to cause the disease. We report a family with typical BBS features (retinitis pigmentosa, postaxial polydactyly, obesity, cognitive impairment, and atrioventricular septal defect) mutated in . IFT27 is part of the Intraflagellar transport (IFT), a bidirectional mechanism allowing the protein motility within the cilia. Using whole exome sequencing, two compound heterozygous mutations were found in the proband (NM_006860.4:c.[104A > G];[349+1G > T], p.[Tyr35Cys];[?]) consistent with the expected autosomal recessive inheritance mode. These two mutations have already been reported but independently in other families and lacking either familial segregation or functional validation. This is the third report of mutations in BBS patients confirming as a BBS gene (). Mutations in IFT genes ( and ) confirm the IFT-pathway as a pathomechanism for BBS.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6363664 | PMC |
| http://dx.doi.org/10.3389/fgene.2019.00021 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Truncating Mutations in BBS10 and BBS12 Impair Proteostasis and Ciliary Architecture in Bardet-Biedl Syndrome.
Exp Eye Res
September 2025
Department of Ophthalmology, Zhengzhou University People's Hospital, Henan Provincial People's Hospital, Henan Eye Hospital, Zhengzhou, Henan, China; Henan Key Laboratory of Ophthalmology and Visual Science, Henan Eye Hospital, Henan Provincial People's Hospital, Zhengzhou, Henan, China; Eye institu
Bardet-Biedl Syndrome (BBS) is a rare autosomal recessive ciliopathy characterized by genetic heterogeneity. Despite significant progress in understanding the BBSome-coding genes associated with ciliopathies, the pathogenesis linked to mutations in chaperonin-coding genes (BBS6, BBS10, and BBS12) remains poorly defined. This study aims to confirm the genetic diagnosis of BBS and elucidate the pathological mechanisms in causative genes of BBS10 and BBS12.
View Article and Find Full Text PDFImpact of the melanocortin-4 receptor agonist setmelanotide on MASLD and kidney function in Bardet-Biedl syndrome.
J Clin Endocrinol Metab
September 2025
Department of Pediatrics II, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Background & Objective: The melanocortin-4 receptor agonist setmelanotide compensates for upstream gene defects in the brain leptin-melanocortin pathway and reduces hyperphagia and obesity in selected monogenic obesity forms and Bardet-Biedl syndrome (BBS). We aimed to evaluate the short-term impact of setmelanotide treatment in BBS presenting original real-world data focusing on metabolic dysfunction-associated steatotic liver disease (MASLD) and kidney function.
Methods: This monocentric, prospective observational cohort study was performed between June and December 2023 and included patients above the age of 6 years with genetically confirmed BBS, obesity and/or hyperphagia and planned setmelanotide therapy.
Real-World Efficacy and Safety of Setmelanotide in Adults With Monogenic or Syndromic Obesity: A Prospective Cohort Study.
Obesity (Silver Spring)
September 2025
Assistance Publique Hôpitaux de Paris, Service de Nutrition, Centre Référent PRADORT "Syndrome de Prader-Willi et Autres Obésités Rares Avec Troubles du Comportement Alimentaire," Hôpital Pitié-Salpêtrière, Paris, France.
Objective: The melanocortin-4 receptor agonist setmelanotide has demonstrated effectiveness in phase 3 clinical trials for patients with monogenic obesity caused by biallelic variants in the leptin receptor (LEPR) and pro-opiomelanocortin (POMC), as well as for individuals with Bardet-Biedl syndrome (BBS). However, real-world evidence remains limited. This study evaluates the long-term effectiveness and safety of setmelanotide in patients who received treatment under a pre-marketing early-access authorization.
View Article and Find Full Text PDFCongenital melanocytic nevi in Bardet-Biedl syndrome.
Orphanet J Rare Dis
August 2025
Department of Internal Medicine, OU-TU School of Community Medicine, Tulsa, USA.
Background: Bardet-Biedl Syndrome (BBS) is a rare obesogenic disorder affecting multiple organs. The diagnosis of BBS is usually difficult and delayed due to this syndrome's wide variety of clinical features. This study aims to assess the rate of congenital melanocytic nevi (CMN) in the BBS population in an effort to bring light to an easily assessable and early manifestation of BBS to aid in earlier diagnosis.
View Article and Find Full Text PDFInherited retinal diseases in Kentucky: diagnostic yield, gene variants, and novel mutations in a U.S. population.
BMC Med Genomics
August 2025
Department of Ophthalmology, Duke University, 2351 Erwin Rd, Durham, NC, 27710, USA.
Background: Inherited retinal diseases (IRDs) are a group of heterogeneous conditions leading to visual impairment and blindness with over 280 associated genes identified so far. This study aims to provide an initial characterization of the clinical and genetic landscape of IRDs in the United States with a cohort from Kentucky and contribute to the existing knowledge from studies in other regions.
Methods: This single-academic center retrospective analysis was conducted on patients seen at the University of Kentucky Ophthalmic Genetic Services from January 2019 to March 2022 with a diagnosis of or concern for unspecified IRD and who underwent subsequent genetic testing with an IRD panel.